Phathom Pharmaceuticals (NASDAQ: PHAT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.970 | -1.070 | -0.1000 | ||||
REV | 210.000K | 0 | -210.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Phathom Pharmaceuticals (NASDAQ: PHAT) through any online brokerage.
Other companies in Phathom Pharmaceuticals’s space includes: GH Research (NASDAQ:GHRS), Aerie Pharmaceuticals (NASDAQ:AERI), WAVE Life Sciences (NASDAQ:WVE), Verona Pharma (NASDAQ:VRNA) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Phathom Pharmaceuticals (NASDAQ: PHAT) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 15.00 expecting PHAT to rise to within 12 months (a possible 74.62% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Phathom Pharmaceuticals (NASDAQ: PHAT) is $8.59 last updated Today at July 1, 2022, 2:36 PM UTC.
There are no upcoming dividends for Phathom Pharmaceuticals.
Phathom Pharmaceuticals’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Phathom Pharmaceuticals.
Phathom Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.